Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey


Cobanoglu N., Ozcelik U., ÇAKIR E., Eyuboglu T. S. , Pekcan S., Cinel G., ...Daha Fazla

PEDIATRIC PULMONOLOGY, cilt.55, ss.2302-2306, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 55 Konu: 9
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1002/ppul.24854
  • Dergi Adı: PEDIATRIC PULMONOLOGY
  • Sayfa Sayıları: ss.2302-2306

Özet

Background A better understanding of cystic fibrosis transmembrane conductance regulator biology has led to the development of modulator drugs such as ivacaftor, lumacaftor-ivacaftor, tezacaftor-ivacaftor, and elexacaftor-tezacaftor-ivacaftor. This cross-sectional study evaluated cystic fibrosis (CF) patients eligible for modulator drugs.